Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer reported $11.12B in Gross Profit on Sales for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last August in 2025.

The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from **** billion U.S. dollars in 2023 to *** billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of **** billion U.S. dollars worldwide, with oncology products accumulating some **** billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around *** and * billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of **** billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under * billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

Pfizer reported $2.97B in Net Income for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Net Income including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Pfizer reported $13.72B in Sales Revenues for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last August in 2025.

In 2024, Pfizer generated total revenues of some **** billion U.S. dollars. For Q1, 2025, the company reported revenues of some **** billion U.S. dollars. That was significantly lower than in the same quarter in 2024. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around **** billion U.S. dollars in 2024. Why Pfizer’s revenues decreased until 2020? Pfizer averaged quarterly revenues of around **** billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the **** billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

Pfizer generated a net income of over eight billion U.S. dollars in 2024. The company reported basic net earnings per common share of 1.42 U.S. dollars. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in the net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to COVID-19 vaccine Thanks to record-breaking sales of COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States accounts for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

Pfizer reported $3.67B in Operating Profit for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Operating Profit including historical, tables and charts were last updated by Trading Economics this last August in 2025.

During 2019, Pfizer’s Lipitor generated nearly *********** U.S. dollars of revenue. For around a decade cholesterol-lowering drug Lipitor was one of the company’s top blockbusters, with record-high revenues of approximately ********** U.S. dollars in 2006. In the year of patent loss – 2011 – Lipitor still generated roughly ********** dollars, before a heavy drop down to ************ dollars in 2012. Pharmaceutical company Pfizer Drug manufacturer Pfizer is headquartered in Midtown Manhattan, New York City. At this moment, it is the world’s leading pharmaceutical company based on pharmaceutical sales of prescribed and over-the-counter drugs. Today, the company is focused on human medicine, divided into two major segments - Innovative Health and Essential Health. However, until 2013 the company also had a notable animal health division which was spun-off and today is known as Zoetis. Facts about Lipitor/atorvastatin Lipitor was approved by the FDA (Food and Drug Administration) in 1996 for medical use. Since its patent protection expired in 2011, it is now also sold under its generic name atorvastatin. Today, atorvastatin is one of the most prescribed drugs in the United States. The drug is primarily used as prevention for people with a high risk for developing cardiovascular diseases and as a treatment for abnormal lipid levels (dyslipidemia). Generic versions of Lipitor lead to annual savings in drug spending of around ********** U.S. dollars.

The net income of Pfizer stood at some ***** billion U.S. dollars in 2024. In the preceding year, the net income was at over *** billion U.S. dollars. What factors affect net income? Companies discover how much they have earned or lost during an accounting period by analyzing their net income. For example, rising costs are among several reasons for the significant fall in Pfizer’s net income in 2020: the company increased its research and development expenditure, and suffered additional costs associated with the restructuring of the organization. It is worth adding that the high net income in 2017 was favorably impacted by a tax benefit of around **** billion U.S. dollars. The pros and cons of mergers and acquisitions Mergers and acquisitions are a common business strategy used by companies looking to grow. ***** of the largest deals in pharmaceutical industry history involve Pfizer, including its acquisition of Warner-Lambert for a record fee of around ** billion U.S. dollars in 2000. Advantages of the tactic include a larger workforce, increased spending budgets, and breaking into new markets. However, a failure to anticipate potential problems can be damaging to a company. For instance, the integration may disrupt current business operations, and inconsistencies may start to appear in standards and procedures.

The graph compares the annual net incomes of major pharmaceutical companies in the United States for the years 2010 and 2022. The x-axis lists the companies, including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, Sanofi, Novartis, Abbott Laboratories, Amgen, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Biogen, Viatris, and Takeda Pharmaceutical. The y-axis represents net income in billions of U.S. dollars. In 2010, Johnson & Johnson led with the highest net income of $13.34 billion, while Viatris had the lowest at $0.224 billion. By 2022, Pfizer's net income surged to $31.37 billion, becoming the highest, whereas AstraZeneca and Takeda Pharmaceutical saw significant declines to $3.29 billion and $2.05 billion, respectively. Most companies, such as GlaxoSmithKline, Merck, and AbbVie, experienced substantial increases in net income over the twelve-year period. However, some companies like Novartis and AstraZeneca faced reductions in their earnings. The data is presented in a grouped bar chart format, highlighting the changes in annual net income for each pharmaceutical company between 2010 and 2022.

Pfizer reported $4.44B in Pre-Tax Profit for its fiscal quarter ending in December of 2024. Data for Pfizer | PFE - Pre Tax Profit including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Pfizer reported $5.93B in EBIT for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Ebit including historical, tables and charts were last updated by Trading Economics this last August in 2025.

The graph displays the top pharmaceutical companies in the United States ranked by their total penalties. The x-axis lists the companies, including Johnson-Johnson, Pfizer, Merck, Teva Pharmaceutical Industries, GlaxoSmithKline, Purdue-Pharma, AbbVie, Endo International, Takeda Pharmaceutical, and Eli Lilly. The y-axis represents the penalty amounts in U.S. dollars, ranging from Johnson-Johnson with the highest penalties of $25,197,250,170 down to Eli Lilly with the lowest at $2,831,299,676 . Johnson-Johnson leads significantly in total penalties, followed by Pfizer and Merck, while Eli Lilly incurs the least among the top ten. The data highlights substantial variations in penalty amounts across major pharmaceutical companies, reflecting differences in regulatory compliance and legal challenges within the industry.

Pfizer reported $0.92 in EPS Earnings Per Share for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - EPS Earnings Per Share including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Moderna generated total revenues of some 3.2 billion U.S. dollars in 2024, a massive decrease compared to the years before. The drop was mainly due to the decreasing demand for its COVID-19 vaccine Spikevax. Working hard to produce the first 'blockbuster' Moderna is a clinical stage biotech company that is pioneering messenger RNA (mRNA) therapeutics and vaccines. Beside its COVID-19 vaccine, the company is yet to generate revenues from the sale of potential drugs, and this will remain the same until it successfully completes clinical development and obtains regulatory approval for one of its medicines. Like many other biotech companies, Moderna invests significant amounts of money into research and development projects, and annual costs continue to grow. One of the very first COVID-19 vaccines approved Moderna, in partnership with the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI), was one of the very first to develop a vaccine to fight COVID-19. The vaccine codenamed mRNA-1273 – designed and manufactured in only 25 days – prevents future infections of the novel coronavirus that has caused the pandemic. The Moderna vaccine successfully went through all necessaryclinical phases, and was the second vaccine - after the Biontech/Pfizer vaccine - to be approved for widely usage already in late 2020.

Pfizer reported $132.28B in Market Capitalization this August of 2025, considering the latest stock price and the number of outstanding shares.Data for Pfizer | PFE - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last August in 2025.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Pfizer (PFE): Will Its Growth Strategy Fuel Further Gains?

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Pfizer: (PFE) Vaccine Giant's Next Chapter

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

Pfizer reported $143M in Interest Income for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Interest Income including historical, tables and charts were last updated by Trading Economics this last August in 2025.